Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline NicoDerm CQ "only" three-step system claims to be modified, NAD reports.

This article was originally published in The Tan Sheet

Executive Summary

SMITHKLINE NICODERM CQ UNIQUENESS CLAIMS TO BE MODIFIED in response to a complaint filed with the National Advertising Division of the Council of Better Business Bureaus by Novartis, which markets the Rx nicotine smoking cessation patch Habitrol. In a Jan. 13 NAD Case Report, the advertising review group details how SmithKline Beecham has agreed to modify claims appearing in a "Commit to Quit" newspaper ad and promotional pamphlet that portray NicoDerm CQ as "the only patch that gradually reduces your nicotine dose in three simple steps" and the "only patch that can be used by light and heavy smokers."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087981

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel